Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib and Ruxolitinib in JAK Inhibitor Naive Myelofibrosis
NCT07357727Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 22
01
Overview
A Phase 3 trial of pelabresib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Novartis. Started May 2026; status: recruiting.
02
Drugs
pelabresib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT07357727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357727.